COMPASS THERAPEUTICS INC

Company Overview

Compass Therapeutics is a clinical‑stage oncology biopharma focused on bispecific and monoclonal antibodies that modulate angiogenesis and anti‑tumor immunity. Its lead asset, tovecimig (DLL4×VEGF‑A), is in a randomized Phase 2/3 biliary tract trial (primary ORR met; pooled OS/PFS analyses now targeted Q1 2026), and the pipeline also includes CTX‑471, CTX‑8371 and IND‑enabling CTX‑10726 with multiple near‑term readouts and IND aims through 2025–2026. The company runs an R&D‑centric model (internal discovery, outsourced clinical manufacturing), holds broad IP (>90 patents/pending), maintains key collaborations (ABL Bio, Adimab), has no product revenue and had a cash runway into 2027 as of mid‑2025. Business cadence is milestone‑driven—clinical enrollments, data readouts, regulatory filings and financings are the primary value and timing drivers.

Executive Compensation Practices

Given no product revenue and rising R&D spend (R&D $42.3M in 2024; accelerating YTD in 2025), Compass’s executive pay is likely weighted toward equity and performance‑contingent incentives to conserve cash while aligning management to long‑dated clinical outcomes. The filings disclose material stock‑based compensation (total ~ $8.56M in 2024) and a CEO transition that increased share‑based pay, consistent with sector norms of modest base salaries plus options/RSUs and milestone or retention awards tied to IND/BLA filings, positive trial readouts (ORR, OS/PFS), licensing events and commercial milestones. Management may also receive short‑term bonuses or milestone payments on achievement of pivotal trial endpoints or licensing milestones, and change‑of‑control/retention provisions are plausible given the company’s dependence on partnerships and potential M&A interest. Accounting and tax factors (e.g., Section 382 limitations on NOL use after ownership changes) and the need for future financings are likely to influence the structure and timing of equity awards.

Insider Trading Considerations

Clinical data readouts, IND/BLA submissions and financings represent frequent sources of material nonpublic information for Compass, so expect strict blackout windows around pooled OS/PFS analyses (Q1 2026), the CTX‑8371 expansion/data cadence (late‑2025/2026) and CTX‑10726 IND activity. Management historically used ATM sales and may pursue equity financings, so insider transactions around capital raises (or option exercises tied to vesting) can reflect liquidity needs rather than conviction; conversely, open‑market insider purchases would be a stronger bullish signal for a cash‑burning, non‑revenue biotech. Standard regulatory constraints apply (Section 16 reporting, short‑swing profit rules) and many executives in this sector use pre‑arranged 10b5‑1 plans or firm‑imposed blackout policies to mitigate timing‑risk on clinical updates and collaborator negotiations.